Patient Safety
Report Side Effects & Adverse Events
Effective Date: May 13, 2026 · Last Revised: May 13, 2026
If you are experiencing a life-threatening reaction — call 911 immediately. This page tells you how to report non-emergency side effects and quality concerns to TelePeptide Health and, independently, to the U.S. FDA.
Quick Contact
Patient Portal Form
1. When to Report
Please tell us about any side effect, adverse reaction, allergic response, suspected medication quality issue, or unexpected outcome associated with a TelePeptide Health program or medication — including issues that started after you stopped a medication. We want to hear from you whether the event seemed minor or serious, and whether you are sure the medication caused it or not. For LIFE-THREATENING SYMPTOMS — severe chest pain, trouble breathing, severe abdominal pain that does not stop, signs of a severe allergic reaction such as facial swelling or throat tightness, or loss of consciousness — CALL 911 or go to the nearest emergency room IMMEDIATELY. Do not wait to contact TelePeptide.
2. How to Report to TelePeptide
You can reach our clinical safety team three ways, every day, all year: (a) Email: safety@telepeptide.org — this inbox is monitored daily and routed directly to our clinical team. Please include your full name, date of birth, the program or medication involved, the date the event started, a description of what happened, and any actions you have taken so far. (b) Phone: (201) 449-3080 — leave a voicemail with your name and the best callback number; our clinical team returns adverse-event calls within one business day. (c) Patient portal: sign in at telepeptide.org/portal/login and use the "Report a side effect" form. Reports filed through the portal create a time-stamped record linked to your medical chart. If your prescription was dispensed by a 503A or 503B compounding pharmacy partner, we will also coordinate with that pharmacy on your behalf to ensure their internal pharmacovigilance file is updated.
3. Reporting Directly to the FDA (MedWatch)
You also have the right to report directly to the U.S. Food and Drug Administration through the MedWatch Adverse Event Reporting Program. Reports help the FDA identify safety signals for both FDA-approved drugs and compounded medications. Online: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program By phone: 1-800-FDA-1088 (1-800-332-1088) By fax: 1-800-FDA-0178 By mail: MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20857 You may file a MedWatch report independently of, before, or after notifying TelePeptide. We encourage patients with serious or unusual events to file both reports — this contributes to the wider safety surveillance system that protects everyone.
4. Reporting a Pharmacy Quality Concern
If you suspect a compounded medication you received is contaminated, mislabeled, the wrong strength, or otherwise defective — stop using it immediately and contact us at safety@telepeptide.org with photos of the vial, label, and packaging if possible. Save the medication for evaluation; do not discard it until we have advised next steps. You may also report compounded-drug quality issues directly to: - Your state Board of Pharmacy (which licenses 503A pharmacies) - The FDA's MedWatch program (contact information above), which oversees 503B outsourcing facilities
5. What Happens After You Report
Every report we receive is triaged by a clinician within one business day. Depending on severity we will: (a) acknowledge receipt and ask clarifying questions; (b) coordinate clinical follow-up with the prescribing physician; (c) coordinate with the compounding pharmacy if a quality issue is suspected; (d) recommend stopping or adjusting the medication if clinically indicated; (e) document the event in your medical record; and (f) escalate to FDA MedWatch when criteria for mandatory or voluntary reporting are met. We will never charge you for an adverse-event consultation. We track aggregate adverse-event data internally and review it quarterly with our clinical leadership to identify patterns and improve patient safety.
6. Confidentiality and Anti-Retaliation
Reports of side effects are treated as Protected Health Information (PHI) under our HIPAA Notice of Privacy Practices at /privacy-practices. We do not share patient-identified reports with the pharmacy or the FDA without your authorization, except as required by law for serious or life-threatening events. You will never be charged, billed, dropped from a program, or otherwise penalized for reporting a side effect or quality concern — full stop.
7. Known Risks We Disclose Up Front
GLP-1 receptor agonists (compounded semaglutide and tirzepatide) commonly cause nausea, vomiting, diarrhea, constipation, indigestion, decreased appetite, headache, and fatigue. Less commonly, gallbladder issues, pancreatitis, kidney problems, and injection-site reactions. Boxed-warning class effects for branded GLP-1s include thyroid C-cell tumors in rodents and possible risk in humans with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Sermorelin and other GHRH analogs can cause injection-site redness, headache, flushing, dizziness, and transient elevations in growth-hormone or IGF-1. NAD+ injections may cause flushing, brief nausea, or injection-site soreness. BPC-157, CJC-1295/Ipamorelin, and other peptides have less FDA-evaluated safety data; we discuss specific risks at the time of prescribing. This list is not exhaustive. The full informed consent at /medical-consent contains additional risk information. Always discuss risks with your prescribing clinician before starting or changing a medication.
8. Compounded Medications — Regulatory Context
Compounded medications dispensed through TelePeptide are not FDA-approved finished drug products. They are prepared by state-licensed 503A or FDA-registered 503B compounding pharmacies. The FDA has not independently verified the safety, efficacy, potency, or sterility of compounded versions of these medications. Because compounded products are not subject to the same post-market surveillance as FDA-approved drugs, patient-reported adverse events are especially important for identifying quality and safety issues. Your report matters.
Related Documents
- Informed Medical Consent — full risk disclosure
- Notice of Privacy Practices — how we handle health information
- Privacy Policy
- Terms of Service
TelePeptide Health · 2077 Center Ave, Apt 9J, Fort Lee, NJ 07024 · safety@telepeptide.org